Abstract:A randomized cross-over pharmacokinetic study of rosuvastatin calcium (single dose: 5 mg, 10 mg and 20 mg; multiple doses: 10mg once daily for 7 days) was conducted in 12 healthy Chinese volunteers. Plasma concentrations of rosuvastatin were determined by an LC-ESI-MS-MS method. Single-nucleotide polymorphisms (SNPs) in ABCB1, ABCG2, SLCOB1, CYP2C9 and CYP3A5 were determined by TaqMan (MGB) genotyping assay. An impact of the aforementioned SNPs on steady state pharmacokinetic parameters [average steady state concentration (Cav,ss) and area under the plasma concentration versus time curve during the dosing interval at steady state (AUCss)], dose-normalized (based on 5 mg) pharmacokinetic parameters of single-dose rosuvastatin were further analyzed. Rosuvastatin exhibited linear pharmacokinetics and great inter-subject variability. Cav,ss, AUCss and dose-normalized peak plasma concentration (Cmax) and AUC(0-infinity) of single-dose rosuvastatin were significantly related with ABCB1 C1236T, G2677T/A and C3435T polymorphisms and ABCB1 haplotypes. Compared to homozygous wild type and heterozygous mutation gene carriers, subjects carrying the variant ABCB1 1236TT, 2677 non-G or 3435TT genotype had higher Cav,ss, AUCss, Cmax and AUC(0-infinity) (p < 0.05). ABCB1 haplotype (1236TT-2677TT-3435TT) had significant influence on dose-normalized pharmacokinetics of single-dose rosuvastatin. ABCB1 haplotype (1236TT-2677TT-3435TT) carriers (n = 12) had obvious higher Cmax (11.16 +/- 3.10 microg x L(-1) vs 8.35 +/- 3.31 microg x L(-1), p < 0.05) and AUC(0-infinity) (86.61 +/- 24.32 microg x h x L(-1) vs 62.60 +/- 26.19 microg x h x L(-1), p < 0.05) compared to non-1236TT-2677TT-3435TT carriers (n = 24). ABCG2 c.421C > A had a significant impact on rosuvastatin pharmacokinetics. Homozygotes (AA) carriers had obvious higher Cmax (12.20 +/- 4.09 microg x L(-1) vs 8.70 +/- 3.09 microg x L(-1), p < 0.05) and AUC(0-infinity) (98.74 +/- 25.36 microg x h x L(-1) vs 64.97 +/- 24.90 microg x h x L(-1), p < 0.05) values compared to heterozygotes (CA) and homozygotes (CC) carriers. There were no significant effects on single-dose and steady-state pharmacokinetics of rosuvastatin by CYP2C9*3 (1075A > C), CYP3A5*3 g.6986A > G, ABCG2 c.34G > A, SLCO1B1 c.521 T > C, c.388 A > G, g.11187 G > A, c.571 T > C and c.597 C > T. In addition, no difference in rosuvastatin pharmacokinetics was observed among subjects of different genders. We conclude that ABCB1 C1236T, G2677T/A and C3435T polymorphism, ABCB1 haplotypes and ABCG2 c.421C > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics in healthy Chinese volunteers, and potentially affect the efficacy and toxicity of statin therapy.

Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with Abcg2 34g > A and 421c > A Homozygote or Compound Heterozygote

ABCB1 Gene Polymorphisms, ABCB1 Haplotypes and ABCG2 C.421c > A Are Determinants of Inter-Subject Variability in Rosuvastatin Pharmacokinetics.

Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.

Statin Intolerance-An Asian Perspective

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

The Association between ABCG2 421C>A (rs2231142) Polymorphism and Rosuvastatin Pharmacokinetics: A Systematic Review and Meta-Analysis

The Effect of Na+/taurocholate Cotransporting Polypeptide (NTCP) C.800c > T Polymorphism on Rosuvastatin Pharmacokinetics in Chinese Healthy Males.

Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States

ABCB1 Haplotype Influences the Sirolimus Dose Requirements in Chinese Renal Transplant Recipients.

Effect of Polymorphisms in CYP3A4, PPARA, NR1I2, NFKB1, ABCG2 and SLCO1B1 on the Pharmacokinetics of Lovastatin in Healthy Chinese Volunteers.

CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T Are Determinants of Inter-Subject Variability in Fluvastatin Pharmacokinetics in Healthy Chinese Volunteers.

CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin.

Simvastatin Pharmacokinetics in Healthy Chinese Subjects and Its Relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 Polymorphisms.

[Effect of OATP1B1 521T --> C Heterogenesis on Pharmacokinetic Characterstics of Rosuvastatin in Chinese Volunteers].

CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 Genetic Polymorphisms and Gender Are Determinants of Inter-Subject Variability in Pitavastatin Pharmacokinetics.

The Effect of Herbal Medicine Baicalin on Pharmacokinetics of Rosuvastatin, Substrate of Organic Anion‐transporting Polypeptide 1B1

Pharmacodynamic Effects and Kinetic Disposition of Rabeprazole in Relation to CYP2C19 Genotype in Healthy Chinese Subjects1

Slco1b1 521t -> C Functional Genetic Polymorphism And Lipid-Lowering Efficacy Of Multiple-Dose Pravastatin In Chinese Coronary Heart Disease Patients

The ABCB1 C3435T Polymorphism is Associated with Triglyceride Reduction in Atorvastatin-treated Uygur Patients with Coronary Heart Disease and Dyslipidemia: An Observational Study

The Influence of Genetic Polymorphisms in Drug Metabolism Enzymes and Transporters on the Pharmacokinetics of Different Fluvastatin Formulations

The Effect of Slco1b1 Polymorphism on the Pharmacokinetics of Atorvastatin and 2-Hydroxyatorvastatin in Healthy Chinese People